AzTrials
AzTrials

CognitionNCT07782229

Appetite and Cognition Response to a Breakfast Cereal

A study testing Ready-To-Eat Cereal in people with Cognition, run by General Mills at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to examine appetite and cognition responses following consumption of a ready-to-eat breakfast cereal. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Cognition
What is being tested?
Ready-To-Eat Cereal
Could I receive a placebo?
No, everyone receives an active treatment
How many people
184 participants
Where
1 siteUnited States
Study dates
14 Sep 2026to 21 Sep 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy adults 18-70 years
  • Habitual breakfast cereal consumers (at least several times per month)
  • Body mass index 18.5-29.9 kg/m2 (based on self-reported weight and height)
  • Understand and willing to follow the study procedures, including having access to a tablet or laptop to use the online platforms for appetite and cognition measurement
  • Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial
  • Willing to abstain from strenuous exercise, consuming alcoholic drinks 24 hours before the test day
  • Willing to provide informed consent to participate in the study

Who cannot join

  • Age or body mass index outside of the inclusion criteria
  • Pregnant or lactating women, or women who are planning to become pregnant during the study
  • Known food allergies, sensitivities, or intolerance to any food or food ingredients
  • Participating in another clinical trial for food, investigational drug, nutritional supplement, or lifestyle modification
  • Taking medications that affect appetite, metabolism or blood pressure
  • Presence of acute diseases or infection
Show all 14Show fewer
  • Presence or history of chronic diseases
  • Diagnosed with an eating disorder
  • Restraint eaters as determined by a score >4 from the Dutch Eating Behavior Questionnaire1
  • Lost or gained 5 or more pounds in the past 3-months
  • On a weight loss diet or undergoing intermittent fasting
  • COVID-19 infection within the past 3 months
  • Subjects who do not eat cereal products
  • Subjects who do not understand or are not willing to follow the study procedures

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Taylor Banh, PhD contact

763-764-7600

taylor.banh@genmills.com

United States1 site, 1 recruiting
  • Remote

    Minneapolis, Minnesota, 55430

    Taylor Banh, PhD, 763-764-7600, taylor.banh@genmills.com

    Recruiting

Other trials in United States

About this study

The purpose of this study is to examine appetite and cognition responses following consumption of a ready-to-eat breakfast cereal.

Conditions
Cognition
Being tested
Ready-To-Eat Cereal
Keywords
cognition, appetite

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ready-To-Eat CerealOther

    Packaged Ready-To-Eat Cereal product available in retail stores

Study groups in NCT07782229
Study groupRoleWhat they receive
Ready-To-Eat CerealExperimentalPackaged ready-to-eat cereal available in retail stores
Receives: Other: Ready-To-Eat Cereal
ControlNo interventionNo intervention (i.e., no food provided)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rapid Visual Information Processing Task

    This computer-based task requires participants to monitor a continuous stream of digits (1-9) presented one at a time on-screen and press the space bar when they detect three consecutive odd or three consecutive even digits. Both accuracy and reaction time will be evaluated.

    Measured: 210 minutes

  2. Visual Analogue Scales for Appetite

    This VAS questionnaire requires participants to score from 0-100 millimeters (mm) on 6 questions relating to: hunger, fullness, satiation, desire to eat, prospective consumption and satisfaction.

    Measured: 240 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Aug 2026
  2. Study start14 Sep 2026 (estimated)
  3. Primary completion21 Sep 2026 (estimated)
  4. Study completion21 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
184 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07782229
Sponsor's protocol ID
0959
Status last verified
Aug 2026
First submitted
19 Aug 2026
Last updated
24 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Ready-To-Eat Cereal in people with Cognition, run by General Mills at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Taylor Banh, PhD (763-764-7600, taylor.banh@genmills.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rapid Visual Information Processing Task (time frame: 210 minutes). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in